WO2019211563A1

WO2019211563A1 - Topical use of oil of seeds of at least one umbelliferous plant for a soothing effect on reactive skin

Info

Publication number: WO2019211563A1
Application number: PCT/FR2019/051012
Authority: WO
Inventors: Catherine KERN
Original assignee: Societe D'exploitation De Produits Pour Les Industries Chimiques Seppic
Priority date: 2018-05-04
Filing date: 2019-05-02
Publication date: 2019-11-07
Also published as: FR3080770A1; CN112236200A; KR20210003865A; EP3787756A1; JP2021522287A; FR3080770B1

Abstract

The use of at least one oil of seeds of at least one umbelliferous plant as a cosmetic active ingredient that can be administered topically for preventing or slowing down the occurrence of dysesthetic sensations on sensitive human skin.

Description

Topical use of seed oil of at least one umbelliferous plant for a soothing effect of reactive skin

The present invention relates to the use of at least one seed oil of an umbelliferous plant to prevent or slow the onset of dysaesthesic sensations on human sensitive skin.

The skin is the first barrier of protection of the body vis-à-vis the environment. It therefore undergoes many external aggressions that can lead to skin reactions of discomfort or even, in the case of very intense or more serious reactions, skin irritation and / or inflammation. Skin discomfort reactions can be induced by contact with chemicals such as cleansers, perms, hair coloring or from mechanical actions such as shaving, exfoliation, peeling, hair removal. , or come from the action of temperature, climate, ultraviolet radiation or even air pollution.

Sensitive or reactive skin is particularly exposed to the consequences of these external aggressions. Sensitive or reactive skin is a condition that affects many people: about 50% of people (60% of women, 40% of men) report having reactive skin. It was recently defined as "a syndrome defined by the appearance of unpleasant sensations (tingling sensations, burning, pain, pruritus and tingling) in response to stimuli that normally should not cause such sensations. sensations can not be explained by lesions related to skin diseases.The skin may look normal or present in addition to erythema.Sensitive skin can affect all areas of the body, especially the face "(1) .

Environmental factors such as exposure to ultraviolet radiation, air pollution, climate (hot, cold, wind), lifestyle (eating habits or cosmetics), or physiological factors such as Endogenous hormones have been known to induce or aggravate the symptoms of sensitive skin (2). Two main reasons can explain the symptoms of sensitive skin: on the one hand an increase in the permeability of the stratum corneum, on the other hand an acceleration of nerve responses (3). Indeed, several studies have shown a link between sensitive skin and disturbance of the barrier function, resulting in the perception of skin discomfort. Altered barrier function has also been associated with atopic dermatitis and it has been shown that people with sensitive skin have an increased incidence of atopy and a higher risk of developing allergies. Finally, people with atopic dermatitis report having sensitive skin, with 80% of them declaring moderate to very sensitive. These data suggest that a link may exist between atopic dermatitis and sensitive skin (2).

Moreover, in view of the sensations described in sensitive skin, it is highly likely that sensitive skin has a neurosensory dysfunction, that is, that the nerve endings on the surface of the skin are less protected because of the alteration of the skin barrier. or that they exhibit hyperreactivity. Cutaneous nerve fibers, such as non-myelinated C-fibers, induce pain and itching sensations, and carry on their surface sensory neuroreceptors such as TRP (transient receptor potential) channels, which are known to induce sensations. pain, burning and itching in sensitive skin (3).

In particular, TRPA1 (Transient Receptor Potential Ankyrin 1) is a nociceptor channel present on the surface of the fibers C but also keratinocytes, melanocytes and fibroblasts and which can be activated by a number of exogenous factors (low temperatures, mustard oil - including AITC or allyl isothyocyanate, environmental pollutants, certain pruritogenic agents ...) and endogenous (reactive oxygen species, nitric oxide, lipid oxidation products) . It is also under the control of intracellular sensitization processes involving several inflammatory mediators such as growth factors, bradykinins, certain proteases and cytokines (4).

TRPA1 is involved in a number of physiological and cellular processes in humans, including nociception, particularly in response to chemical irritants, itching / pruritus, neurogenic inflammation and thermosensation (5). For example, TRPA1 is involved in transmitting histamine-independent itch sensations to the central nervous system. The expression of TRPA1 in the nerve endings is higher in lesions of patients with atopic dermatitis. TRPA1 has also been implicated in the cycles of itching / scratching caused in dry skin, which is consistent with the fact that TRPA1 is an essential sensor of skin barrier aggression (6).

The appearance of signs of discomfort, within minutes of contacting the subject with the triggering element, is one of the essential features of sensitive skin with neurosensory dysfunction.

These signs of discomfort are mainly dysaesthetic sensations. By dysaesthetic sensations are meant more or less painful sensations felt in a cutaneous area such as tingling, tingling, itching, burning, heating, discomfort, tightness.

The cosmetic and / or dermatological and / or nutritional compositions that can be used to prevent or slow the onset of dysaesthesic sensations on sensitive skin, and more particularly tingling, tingling, itching, tugging, can be administered by oral or topically. They generally comprise fatty phases consisting of at least one oil of plant, animal, mineral or synthetic origin. Among these oils, vegetable oils are widely used because the trend of the market is oriented towards the use of products from the natural world.

Vegetable oils consist mainly of triglycerides, which are distinguished by different types of fatty chains and which, after glycerolysis, provides access to a characteristic fatty carboxylic acid distribution.

Vegetable oils are therefore distinguished from essential oils of plants because essential oils are odoriferous products obtained from a plant material, usually by steaming. An essential oil extracted from a plant can therefore not contain fatty triglycerides.

Among these fatty carboxylic acids present as triglycerides in vegetable oils, petroselinic acid or (Z) -octadec-6-enoic acid is known for its use in the treatment or prophylaxis of diseases of the skin or scalp . The international patent application published under the number WO 99/02149 A1 describes in particular use against inflammation related to psoriasis, erythema (sunburn), eczema, seborrheic dermatitis, alopecia a reata, mycosis , acne or other dermatoses, for example. Applications can also be extended to inflammations of the eye (inflammation of the cornea) and mucous membranes, including mucous membranes oral, nasal, oral and vaginal. The international patent application published under the number WO 99/02149 A1 also discloses that a composition comprising petroselinic acid can be administered orally so that the petroselinic acid can act on the mucous membranes (the oral mucous membranes of the body). esophagus, stomach and intestinal), and / or it can pass into the bloodstream and be brought directly to the cells of the skin, eye or mucous membranes.

Petroselinic acid is more particularly present in oils from an umbellifer, a plant whose flowers are arranged in umbels.

In the cosmetics field, coriander has been used as an ingredient in the traditional Ayurvedic cosmetic formula (Varnakarlepa) to normalize skin color (7). On the other hand, the described effects relate to the essential oil of coriander, and not the coriander seed oil (8).

The effects of coriander are known and more particularly on the skin: the coriander essential oil is described for these inflammatory effects (9).

Coriander seed powder showed an anti-inflammatory effect in vivo in an inflammatory model of carrageenan-induced edema in rats (10). While coriander oil showed an anti-radical effect in tubo, it did not show any anti-inflammatory effect in the same in vivo model as previously (11).

According to the same study model, coriander oil did not reduce paw edema in rats (12).

The coriander extracts, obtained by extraction with hexane or methanol, showed in vitro activity on the inhibition of the enzymes cycloxygenase-1 and -2 (13). Nevertheless, the signaling pathways involved between cyclooxygenases / lipoxygenases on the one hand and the activation of sensory neurons on the other hand are not correlated, and no effect on the sensations of itching, pruritus or discomfort have have been observed or demonstrated.

The European patent application published under the number EP0888773 A1 relates to the use of petroselinic acid for the treatment of superficial tissue inflammations, in particular for the preparation of a composition intended to activate the peroxisomal b-oxidation of fatty acids. in the superficial tissues of a mammal so as to be able to treat or prevent inflammation and / or modulate the lipid metabolism of the superficial tissues has been abandoned because of a state of the art deemed too important. But nothing in EP0888773 A1 discloses the use of coriander seed oil to prevent and / or reduce the sensations of discomfort resulting from sensitive or reactive skin, and in particular the sensations of itching, pruritus, tingling, tingling, itching, tugging.

The US patent published under the number US6365175 relates to the use of petroselinic acid in the food field, and in particular to prepare dietary supplement compositions used as anti-inflammatory compositions that inhibit the production of acid metabolites. arachidonic and / or reduce the formation of intracellular adhesion molecules or anti-aging compositions. But nothing in US6365175 discloses or teaches the use of coriander seed oil to prevent and / or lessen the sensations of discomfort resulting from sensitive or reactive skin, and particularly the sensations of itching, pruritus, tingling, tingling, itching, tugging.

As part of his research on the treatment of sensations

dysaesthetic on human sensitive skin, the inventor focused on developing a new composition with positive effects on sensitive skin.

According to a first aspect, the subject of the invention is a use of at least one seed oil of at least one umbelliferous plant as a cosmetic active ingredient.

administrable topically to prevent or slow the onset of dysaesthesic sensations on human sensitive skin.

For the purposes of this application, the term "dysaesthetic sensations" is understood to mean sensations felt in a cutaneous zone, such as tingling, tingling, itching, burning, heating, tugging.

The seed oils of such umbelliferous plants are obtained by the implementation of a process comprising at least one step of grinding the seeds and / or at least one step of pressing the seeds, and at least one subsequent step of refining the liquid. oily obtained after the grinding and / or pressing step.

It is preferable to use coriander seed oil.

Depending on the case, the use according to the invention may have one or more of the following characteristics:

the umbelliferous plant is chosen from coriander, chervil, celery, caraway, carrot, dill, parsley and fennel,

- the umbelliferous plant is coriander, the seed oil of an umbelliferous plant comprises, for 100% of its mass, a mass proportion of at least one triglyceride greater than or equal to 99%, with the triglyceride being a compound of formula (I):

R ₁ -C (= O) -O-CH ₂ -CH [OC (= O) -R ₁ ] -CH ₂ -OC (= O) -R ₁ (I) With R ₁ -C (= O) - acyl radical selected from the group consisting of palmitoyl (or hexadecanoyl), stearoyl (or octadecanoyl), petroselinoyl (or (Z) -octadec-6-enoyl), oleyl (or cis-octadec-9-enoyl), and linoloyl (or cis, cis-9,12-octadecadienoyl), linolenoyl (or (9Z, 12Z, 15Z) -9,12,15-octadecatrienoyl),

the seed oil of an umbelliferous plant comprises, for 100% of the mass of triglycerides of formula (I), a mass quantity of between 40% and 85%, and more particularly between 55% and 80%, and even more especially between 60% and 75%, of a triglyceride of formula (I) for which the radical R1C (= O) - is the petroselinoyl radical (or (Z) -octadec-6-enoyl),

the seed oil of an umbelliferous plant comprises for 100% of the mass of triglycerides of formula (I): a mass quantity of between 2% and 5% of a triglyceride of formula

(I) for which the radical R1C (= O) - is the palmitoyl radical, and / or a mass quantity of between 0% and 1.5% of a triglyceride of formula (I) for which the radical R1C (= O ) - is the stearoyl radical, and / or a mass quantity of between 60% and 75% of a triglyceride of formula (I) for which the radical R1C (= O) - is the petroselinoyl (or (Z) -octadec radical; -6- enoyl), and / or a mass quantity of between 8% and 15% of a triglyceride of formula

(I) for which the radical R1C (= O) - is the oleyl radical, and / or a mass quantity of between 12% and 19% of a triglyceride of formula (I) for which the radical R1C (= O) - is the linoleoyl radical, and / or a mass quantity of 0% and 1% of a triglyceride of formula (I) for which the radical R1C (= O) - is the linolenoyl radical.

The present invention also relates to a cosmetic or dermatological formulation for topical use comprising for 100% of its mass:

from 0.5% to 50% by weight of at least one seed oil of an umbelliferous plant as defined in one of claims 1 to 6, and

from 50% to 99.5% by weight of at least one cosmetically acceptable ingredient.

The expression "cosmetically acceptable" used in the definition of the cosmetic formulation for topical use means according to the directive of the Council of the Community Economic European N ° 76/768 / CEE of July 27, 1976 modified by the directive n ° 93/35 / CEE of June 14, 1993, that said formulation includes any substance or preparation intended to be put in contact with the various parts of the human body (epidermis, hair and hair system, nails, lips and genitals) or with the teeth and oral mucosa in view, exclusively and mainly, to clean, perfume, modify the appearance and / or correct body odor and / or protect or maintain it in good condition.

Depending on the case, the formulation according to the invention may have one or more of the following characteristics:

it is in the form of an aqueous or hydro-alcoholic or hydro-glycolic solution, in the form of a suspension, an emulsion, a microemulsion or a nanoemulsion, whether of water-in-oil, oil-in-water, water-in-oil-in-water or oil-in-water-in-oil type, or in the form of a powder.

- It is packaged in a bottle, in a "pump" type device, an aerosol device in pressurized form, in a device with a perforated wall such as a grid or in a device with a ball applicator.

the cosmetically acceptable ingredient is an excipient and / or an active ingredient.

the excipient and / or the active ingredient are chosen from thickening and / or gelling surfactants, stabilizers, film-forming compounds, hydrotropic agents, plasticizing agents, emulsifying and co-emulsifying agents, opacifying agents, agents nacrants, superfatting agents, sequestering agents, chelating agents, antioxidants, perfumes, preservatives, conditioners, bleaching agents for hair and skin discoloration, active principles for providing a treating action against for the skin or hair, sunscreens, mineral fillers or pigments, particles providing a visual effect or intended for the encapsulation of active ingredients, exfoliating particles and texture agents.

Examples of foaming and / or detergent surfactants which may be combined with the topical formulation of the present invention as defined above include anionic, cationic, amphoteric or nonionic foaming and / or detergent surfactants.

Among the foaming and / or detergent anionic surfactants that can be combined with the formulation for topical use that is the subject of the present invention as defined above, mention may be made of the alkali metal, alkaline earth metal, ammonium, amine or alkylalcohol salts of alkylether sulfates, of alkyl sulphates,

alkylamidoether sulphates, alkylaryl polyethersulfates, monoglyceride sulphates, alphaolefin sulphonates, paraffin sulphonates, alkyl phosphates, alkyl ether phosphates, alkyl sulphonates, alkylamide sulphonates, alkylaryl sulphonates, alkyl carboxylates, alkyl sulphosuccinates, alkyl ether sulphosuccinates, alkylamide sulphosuccinates, alkyl sulphoacetates, alkyl sarcosinates, acyl isethionates, N-acyl ta urines, acyl lactylates, N-acyl derivatives amino acids, N-acyl derivatives of peptides, N-acyl derivatives of proteins, N-acyl derivatives of fatty acids.

Among the foaming and / or detergent amphoteric surfactants that may be associated with the topical formulation of the present invention as defined above, mention may be made of alkyl betaines, imidazolines, phosphobetaines, amphopolyacetates and amphopropionates.

Among the foaming and / or detergent cationic surfactants that may be associated with the formulation for topical use that is the subject of the present invention as defined above, mention may be made especially of quaternary ammonium derivatives.

Among the foaming and / or detergent nonionic surfactants that may be associated with the formulation for topical use that is the subject of the present invention as defined above, mention may be made more particularly of alkylpolyglycosides comprising an aliphatic radical, linear or branched, saturated or unsaturated, and having from 8 to 16 carbon atoms, such as octyl polyglucoside, decyl polyglucoside, undecylenyl polyglucoside, dodecyl polyglucoside, tetradecyl polyglucoside, hexadecyl polyglucoside, 1-12 dodecanediyl polyglucoside; ethoxylated hydrogenated castor oil derivatives such as the product marketed under the INCI name "Peg-40 hydrogenated castor oil"; polysorbates such as Polysorbate 20, Polysorbate 40, Polysorbate 60, Polysorbate 70, Polysorbate 80, Polysorbate 85; coconut amides; N-alkylamines.

Examples of thickening and / or gelling surfactants that may be combined with the formulation for topical use that is the subject of the present invention as defined above include fatty esters of alkylpolyglycosides that are optionally alkoxylated, such as ethoxylated methylpolyglucoside esters such as that PEG 120 methyl glucose trioleate and PEG 120 methyl glucose dioleate respectively marketed under the names GLUCAMATE ™ LT and G LU MATE ™ DOE120; alkoxylated fatty esters such as PEG 150 pentaerythritol tetrastearate sold under the name CROTHIX ™

DS53, PEG 55 propylene glycol oleate sold under the name ANTIL ™ 141; fatty chain polyalkylene glycol carbamates such as PPG-14 laureth isophoryl dicarbamate marketed under the name ELFACOS ™ T211, PPG-14 palmeth-60 hexyl dicarbamate sold under the name ELFACOS ™ GT2125.

As examples of thickening and / or gelling agents that may be associated with the formulation for topical use that is the subject of the present invention as defined above, mention may be made of the co-polymers of AMPS and of alkyl acrylates of which the carbon chain comprises between four and thirty carbon atoms and more particularly between ten and thirty carbon atoms, the linear, branched or crosslinked terpolymers of at least one monomer having a strong, free, partially salified or totally salified acid function, with at least one neutral monomer, and at least one monomer of formula (XIII): ## STR2 ##

in which R'3 represents a hydrogen atom or a methyl radical, R'4 represents a linear or branched alkyl radical containing from eight to thirty carbon atoms and n 'represents a number greater than or equal to one and less than or equal to fifty.

Examples of thickening and / or gelling agents that can be combined with the formulation for topical use that is the subject of the present invention as defined above include polysaccharides consisting solely of monosaccharides, such as glucans or homopolymers of glucose. , glucomannoglucans, xyloglycans, galactomannans whose degree of substitution (DS) of D-ga lactose units on the main chain of D-mannose is between 0 and 1, and more particularly between 1 and 0.25, as galactomannans from cassia gum (DS = 1/5), locust bean gum (DS = 1/4), tara gum (DS = 1/3), guar gum (DS = 1/2), fenugreek gum (DS = 1).

Examples of thickening and / or gelling agents that can be combined with the formulation for topical use that is the subject of the present invention as defined above include polysaccharides consisting of monosaccharides, such as sulphated galactans, and more especially carrageenans and agar, uronans and more particularly algin, alginates and pectins, heteropolymers of oses and uronic acids and more especially xanthan gum, gellan gum, exudates of gum arabic and karaya gum, glucosaminoglycans.

Examples of thickening agents and / or gelling agents that can be associated with the topical formulation object of the present invention as defined above, include cellulose, cellulose derivatives such as methyl cellulose, ethyl cellulose, hydroxypropyl cellulose, silicates, starch, hydrophilic derivatives of starch, polyurethanes.

Examples of stabilizing agents that can be combined with the formulation for topical use that is the subject of the present invention as defined above include microcrystalline waxes, and more particularly ozokerite, mineral salts such as sodium or magnesium chloride, silicone polymers such as polysiloxane polyalkyl polyether co polymers.

As examples of solvents that may be associated with the formulation for topical use object of the present invention as defined above, mention may be made of water, organic solvents such as glycerol, diglycerol, oligomers of glycerol, ethylene glycol, propylene glycol, butylene glycol, 1,3-propanediol, 1,2-propanediol, hexylene glycol, diethylene glycol, xylitol, erythritol, sorbitol, water-soluble alcohols such as ethanol , isopropanol or butanol, water mixtures and said organic solvents. As examples of thermal or mineral waters that can be associated with the formulation for topical use object of the present invention as defined above, mention may be made of thermal or mineral waters having a mineralization of at least 300 mg / l, especially Avene water, Vittel water, Vichy basin water, Uriage water, Roche Posay water, Bourboule water, Enghien water -the-baths, the water of Saint-Gervais-les Bains, the water of Néris-les-Bains, the water of Allevard-les-Bains, the water of Digne, the water of the Maizieres, the Neyrac-les-Bains water, Lons le Saunier water, Rochefort water, Saint Christau water, Fumades water and Tercis-les-Bains water.

As examples of hydrotropic agents that can be associated with the composition (CE) for topical use object of the present invention as defined above, there may be mentioned xylenesulfonates, cumenesulfonates, hexylpolyglucoside, 2-ethylhexylpolyglucoside n-heptylpolyglucoside. As examples of emulsifying surfactants which may be associated with the formulation for topical use object of the present invention as defined above, there may be mentioned nonionic surfactants, anionic surfactants, cationic surfactants.

As examples of emulsifying nonionic surfactants that may be associated with the formulation for topical use that is the subject of the present invention as defined above, mention may be made of esters of fatty acids and of sorbitol, such as the products sold under the names MONTANE ™ 40, MONTANE ™ 60, MONTANE ™ 70, MONTANE ™ 80 and MONTANE ™ 85; compositions comprising glycerol stearate and ethoxylated stearic acid between 5 moles and 150 moles of ethylene oxide, such as the composition comprising stearic acid ethoxylated with 135 moles of ethylene oxide and glycerol stearate. marketed under the name SIMULSOL ™ 165; mannitan esters; ethoxylated mannitan esters; sucrose esters; esters of

methylglucoside; alkylpolyglycosides comprising a linear or branched, saturated or unsaturated aliphatic radical containing from 14 to 36 carbon atoms, for instance tetradecyl polyglucoside, hexadecyl polyglucoside, octadecyl polyglucoside, hexadecylpolyxyloside or octadecylpolyxyloside, eicosyl polyglucoside, dodecosyl polyglucoside, 2-octyldodecyl polyxyloside, 12-hydroxystearyl polyglucoside; linear or branched fatty alcohol compositions, saturated or unsaturated, and containing from 14 to 36 carbon atoms, and alkylpolyglycosides as described above, for example the compositions sold under the names MONTANOV ™ 68, MONTANOV ™ 14, MONTANOV ™ 82,

MONTANOV ™ 202, MONTANOV ™ S, M0NTAN0V ™ W018, MONTANOV ™ L, FLU! DANOV ™ 20X and EASYNOV ™.

As examples of anionic surfactants which may be associated with the formulation for topical use object of the present invention as defined above, mention may be made of glyceryl stearate citrate, cetearyl sulphate, soaps such as sodium stearate or triethanolammonium stearate. N-acyl derivatives of salified amino acids, for example stearoyl glutamate.

Examples of emulsifying cationic surfactants which may be combined with the topical formulation of the present invention as defined above include aminoxides, quaternium-82 and the surfactants described in patent application WO96 / 00719. and mainly those whose fatty chain comprises at least 16 carbon atoms. Examples of opacifying and / or nacrating agents that may be associated with the topical formulation of the present invention as defined above include sodium palmitate, sodium stearate, sodium hydroxystearate , magnesium palmitate, magnesium stearate, magnesium hydroxystearate, ethylene glycol monostearate, ethylene glycol distearate, polyethylene glycol monostearate, polyethylene glycol distearate, fatty alcohols having from 12 to 22 carbon atoms. Examples of texturizing agents which may be associated with the formulation for topical use that is the subject of the present invention as defined above, include N-acylated derivatives of amino acids, such as lauroyl lysine marketed under the present invention. AMINOHOPE ™ LL name, octenyl starch succinate marketed under the name DRYFLO ™, myristyl polyglucoside marketed under the name MONTANOV ™ 14, cellulose fibers, cotton fibers, chitosan fibers, talc, sericite , mica

As examples of deodorant agents that can be associated with the formulation for topical use object of the present invention as defined above, there may be mentioned alkali silicates, zinc salts such as zinc sulfate, zinc gluconate, zinc chloride, zinc lactate; quaternary ammonium salts such as cetyltrimethylammonium salts, cetylpyridinium salts; glycerol derivatives such as glycerol caprate, glycerol caprylate, polyglycerol caprate; 1,2 decanediol; 1,3 propanediol; salicylic acid; sodium bicarbonate; cyclodextrins; metallic zeolites; TRICLOSAN ™; aluminum bromohydrate, aluminum chlorohydrates, aluminum chloride, aluminum sulphate, aluminum and zirconium hydrochlorides, aluminum and zirconium trihydrochloride, aluminum zirconium tetrachlorohydrate , aluminum and zirconium pentachlorohydrate, aluminum and zirconium octochlorhydrate, aluminum sulphate, sodium and aluminum lactate, aluminum and glycol hydrochloride complexes, as well as propylene glycol aluminum dihydrochloride complex, aluminum and propylene glycol sesquichlorohydrate complex, polyethylene glycol aluminum aluminum and polyethylene glycol, the complex of aluminum sesquichlorohydrate and polyethylene glycol.

As examples of oils which can be associated with the formulation for topical use object of the present invention as defined above, mention may be made of mineral oils such as paraffin oil, vaseline oil, isoparaffins or mineral white oils; oils of animal origin, such as squalene or squalane; vegetable oils, such as phytosqualane, sweet almond oil, coconut oil, castor oil, jojoba oil, olive oil, rapeseed oil, peanut oil, sunflower oil, wheat germ oil, corn germ oil, soybean oil, cottonseed oil, alfalfa oil, poppy oil , pumpkin oil, evening primrose oil, millet oil, barley oil, rye oil, safflower oil, bancoulier oil, passionflower oil , hazelnut oil, palm oil, shea butter, apricot kernel oil, calophyllum oil, sysymbrium oil, avocado oil, calendula, oils derived from flowers or vegetables vegetable oils ethoxylated; synthetic oils such as fatty acid esters such as butyl myristate, propyl myristate, isopropyl myristate, cetyl myristate, isopropyl palmitate, octyl palmitate, butyl stearate, hexadecyl stearate, isopropyl stearate, octyl stearate, isocetyl stearate, dodecyl oleate, hexyl spleen, propylene glycol dicaprylate, lanolic acid esters, such as isopropyl lanolate, isocetyl lanolate, monoglycerides, diglycerides and triglycerides of fatty acids such as glycerol triheptanoate, alkylbenzoates, hydrogenated oils, poly (alpha-olefin), polyolefins such as poly (isobutane), synthetic isoalkanes such as isohexadecane, isododecane, perfluorinated oils; silicone oils such as dimethylpolysiloxanes, methylphenyl polysiloxanes, amine-modified silicones, fatty acid-modified silicones, alcohol-modified silicones, alcohol-modified silicones and fatty acids, silicone modified with polyether groups, modified epoxy silicones, silicones modified with fluorinated groups, cyclic silicones and silicones modified with alkyl groups. By "oils" is meant herein the compounds and / or the mixtures of water-insoluble compounds having a liquid appearance at a temperature of 25 ° C.

As examples of waxes that can be associated with the formulation for topical use object of the present invention as defined above, include beeswax, carnauba wax, candelilla wax, wax ouricoury , Japanese wax, cork fiber wax, sugar cane wax, paraffin waxes, lignite waxes, microcrystalline waxes, lanolin wax; ozokerite; polyethylene wax; silicone waxes; vegetable waxes; fatty alcohols and solid fatty acids at room temperature; glycerides solid to ambient temperature. By "waxes" is meant in the present application compounds and / or mixtures of water-insoluble compounds having a solid appearance at a temperature greater than or equal to 45 ° C.

Examples of active principles that can be associated with the formulation for topical use object of the present invention as defined above include vitamins and their derivatives, including their esters, such as retinol (vitamin A) and its esters (retinyl palmitate, for example), ascorbic acid (vitamin C) and its esters, ascorbic acid sugar derivatives (such as ascorbyl glucoside), tocopherol (vitamin E) and its esters (as tocopherol acetate), vitamins B3 or B10 (niacinamide and its derivatives); compounds showing a lightening or depigmenting action on the skin, such as w-undecelynoyl phenylalanine marketed under the name SEPIWHITE ™ MSH, SEPICALM ™ VG, the mono ester and / or the glycerol diester of w-undecelynoyl phenylalanine, the w- undecelynoyl dipeptides, arbutin, kojic acid, hydroquinone; the compounds showing a soothing action including SEPICALM ™ S, allantoin and bisabolol; anti-inflammatory agents; compounds showing a moisturizing action such as urea, hydroxyureas, glycerol, polyglycerols, glycerolglucoside, diglycerolglucoside, polyglycerylglucosides, xylitylplucoside; plant extracts rich in polyphenols such as grape extracts, pine extracts, wine extracts, olive extracts; compounds showing a slimming or lipolytic action such as caffeine or its derivatives, ADIPOSLIM ™, ADIPOLESS ™, fucoxanthin; N-acylated proteins; N-acylated peptides such as MATRIXIL ™; N-acyl amino acids; partial hydrolysates of N-acylated proteins; amino acids; peptides; total hydrolysts of protein; soy extracts, for example Raffermi ™; wheat extracts for example TENSINE ™ or GLIADINE ™; plant extracts, such as tannin-rich plant extracts, plant extracts rich in isoflavones or plant extracts rich in terpenes; freshwater or marine algae extracts; marine plant extracts; marine extracts in general such as corals; essential waxes; bacterial extracts; ceramides; phospholipids; compounds exhibiting antimicrobial action or purifying action, such as LIPACIDE ™ CSG, LIPACIDE ™ UG, SEPICONTROL ™ A5; OCTOPIROX ™ or SENSIVA ™ SC50; compounds showing an energizing or stimulating property such as PHYSIOGENYL ™, panthenol and its derivatives such as SEPICAP ™ MP; anti-aging active ingredients like SEPILIFT ™ DPHP, LIPACIDE ™ PVB, SEPIVINOL ™, SEPIVITAL ™, MANOLIVA ™, PHYTO-AGE ™, TIMECODE ™; SURVICODE ™; anti-aging photo active ingredients; the active ingredients protecting the integrity of the dermal-epidermal junction; actives enhancing the synthesis of extracellular matrix components such as collagen, elastins, glycosaminoglycans; assets acting favorably on chemical cellular communication such as cytokines or physical ones such as integrins; active ingredients that create a sensation of "heating" on the skin, such as activators of cutaneous microcirculation (such as nicotinic acid derivatives) or products that create a sensation of "freshness" on the skin (such as menthol and derivatives) ; the active agents improving cutaneous microcirculation, for example the venotonic ones; draining assets; decongestant active ingredients such as extracts of gin ko biloba, ivy, chestnut, bamboo, ruscus, holly, centalla asiatica, fucus, rosemary, willow; tanning agents or skin browning agents, for example dihydroxyacetone (DHA), erythrulose, mesotartaric aldehyde, glutaraldehyde, glyceraldehyde, alloxane, ninhydrin, plant extracts, for example wood extracts red Pterocarpus and Baphia genus such as Pteropcarpus santa linse, Pterocarpus osun, Pterocarpus soyauxii, Pterocarpus erinaceus, Pterocarpus indicus or Baphia nitida as described in European patent application EP 0 971 683; agents known for their action of facilitating and / or accelerating the tanning and / or browning of human skin, and / or for their action of coloring human skin, for example caratenoids (and more particularly beta carotene) and gamma carotene), the product marketed under the tradename "Garrot oil" (INCI name: Daucus Carota, helianthus annuus sunflower oil) by Provital, which contains carotenoids, vitamin E and vitamin K; tyrosine and / or its derivatives, known for their effect on the tanning acceleration of human skin in association with exposure to ultraviolet radiation, for example the product marketed under the brand name "SunTan Accelerator ™" by the P ro vital company which contains tyrosine and riboflavins (vitamin B), the tyrosine and tyrosinase complex marketed under the brand name "Zymo Tan Complex" by Zymo Line, the product sold under the brand name MelanoBronze ™ (INCI name: Acetyl Tyrosine, Monk's pepper extract) by the company Mibelle which contains acetyl tyrosine, product sold under the brand name Unipertan VEG-24/242/2002 (INCI name: butylene glycol and acetyl tyrosine and hydrolyzed vegetable p rote in and adenosine triphosphate) by UNIPEX, the product marketed under the name of mark 'Try-Excell ™' (INCI name: Oleoyl Tyrosine and Luffa Cylindrica (Seed) Oil and Oleic acid) by Sederma which contains extracts of pumpkin seed (or Loofah oil), the product marketed under the name of "Actibronze ™" (INCI name: hydrolyzed wheat protein and acetyl tyrosine and copper gluconate) by the company Alban Muller, the product sold under the brand name Tyrostan ™ (INCI name: potassium caproyl tyrosine) by Synerga, the product sold under the brand name Tyrosinol (INCI name: Sorbitan Isostearate, Glyceryl Oleate, Caproyl Tyrosine) by Synerga, the product sold under the brand name Insta Bronze ™ (INCI name: Dihydroxyacetone and Acetyl Tyrosine and Copper Gluconate) marketed by Alban Muller, the product marketed under the trade name Tyrosilane (INCI name: methylsilanol and acetyl tyrosine) by Exymol; peptides known for their effect of activating melanogenesis, for example the product marketed under the brand name Bronzing SF Peptide powder (INCI name: Dextran and Octapeptide-5) by the company Infinitec Actives, the product marketed under the brand name Melitane (INCI name: Glycerin and Aqua and Dextran and Acetyl hexapeptide-1) including acetyl hexapeptide-1 known for its alpha-MSH agonist action, the product marketed under the brand name Melatimes Solutions ™ (INCI name: Butylene glycol, Palmitoyl Tripeptide-40) by LIPOTEC, sugars and sugar derivatives, for example the product marketed under the trade name Tanositol ™ (INCI name: inositol) by the company Provital, the product marketed under the name of Thalitan ™ brand (or Phycosaccharide ™ AG) by CODIF International (INCI name: Aqua and Hydrolyzed algin (Laminaria Digitata) and magnesium sulfate and manganese sulfate) containing an olig marine origin osaccharide (guluronic acid and mannuronic acid chelated with magnesium and manganese ions), the product marketed under the brand name Melactiva ™ (INCI name: Maltodextrin, Mucuna Pruriens Seed extract) by Alban Muller, rich compounds in flavonoids for example the product marketed under the brand name "Biotanning" (INCI name: Hydrolyzed citrus Aurantium dulcis fruit extract) by the company Silab and known to be rich in flavonoids of lemon (hesperidin type); agents for the treatment of hair and / or hair, for example protective agents of the hair follicle melanocytes, for protecting said melanocytes against the cytotoxic agents responsible for the senescence and / or apoptosis of said melanocytes, such as the mimetics of the activity of DOPAchrome tautomerase chosen from those described in the European patent application published under the number EP1515688 A2, synthetic mimetic molecules of SOD, for example manganese complexes, antioxidant compounds, for example cyclodextrin derivatives, silica compounds derived from ascorbic acid, pyrrolidone carboxylate of lysine or arginine combinations of mono- and diester of cinnamic acid and vitamin C, and more generally those cited in the European patent application published under the number EP 1 515 688 A2.

As examples of antioxidants that can be associated with the formulation for topical use object of the present invention as defined above, mention may be made of EDTA and its salts, citric acid, tartaric acid, oxalic acid, BHA (butylhydroxyanisol), BHT (butylhydroxytoluene), tocopherol derivatives such as tocopherol acetate, mixtures of antioxidant compounds such as DISSOLVINE GL 475 marketed by Akzo Nobel under the name INCI: Tetrasodium glutamate

Diacetate.

As examples of sunscreens that can be associated with the formulation for topical use object of the present invention as defined above, we can cite all those appearing in the cosmetic directive 76/768 / EEC modified Annex VII.

Among the solar organic filters that can be associated with the formulation for topical use object of the present invention as defined above, include the family of benzoic acid derivatives such as para-aminobenzoic acids (PABA), including the monoglycerol esters of PABA, the ethyl esters of N, N25 propoxy PABA, the ethyl esters of N, N-diethoxy PABA, the ethyl esters of N, Ndimethyl PABA, the methyl esters of N, N-dimethyl PABA, the esters butyl N, Ndimethyl PABA; the family of anthranilic acid derivatives such as homomenthyl-N-acetyl anthranilate; the family of salicylic acid derivatives such as amyl salicylate, homomenthyl salicylate, ethylhexyl salicylate, phenyl salicylate, benzyl salicylate, p-isopropanolphenyl salicylate; the family of cinnamic acid derivatives such as ethylhexyl cinnamate, ethyl-4-isopropyl cinnamate, methyl-2,5-diisopropyl cinnamate, p-methoxypropyl cinnamate, p-methoxyisopropyl cinnamate p-methoxyisoamyl cinnamate, p-methoxyoctyl cinnamate (pmethoxy-2-ethylhexyl cinnamate), p-methoxy-2-ethoxyethyl cinnamate, methoxycyclohexyl p-cinnamate, ethyl-a-cyano cinnamate, -b-phenyl, 2-ethylhexyl-α-cyano-b-phenyl cinnamate, glyceryl diparamethoxy mono-2-ethylhexanoyl cinnamate; the family of benzophenone derivatives such as 2,4-dihydroxybenzophenone, 2,2'-dihydroxy-4-methoxybenzophenone, 2,2 ', 4,4'-tetrahydroxybenzophenone, 2-hydroxy-4-methoxybenzophenone, 2 4-hydroxy-4-methoxy-4'-methylbenzophenone, 2-hydroxy-4-methoxybenzophenone-5-sulfonate, 4-phenyl benzophenone, 2-ethylhexyl-4'-phenylbenzophenone-2-carboxylate, 2-hyd Roxy-4-n-octyloxyhexylone, 4-hydroxyoxy-3-carboxylic acid; 3- (4'-methylbenzylidene) -d, 1-camphor, 3 (benzylidene) -d, camphor, benzalkonium methosulfate camphor; urocanic acid, ethyl urocanate; the family of sulfonic acid derivatives such as 2-phenylbenzimidazole sulfonic acid-5 and its salts; the family of triazine derivatives such as hydroxyphenyl triazine, ethylhexyloxyhydroxyphenyl-4-methoxyphenyltriazine, 2,4,6-trianillino- (p -carbo-2'-ethylhexyl-1'-oxy) -1,3, 5-triazine, 4,4 - ((6 - (((1,1-dimethylethyl)

amino) carbonyl) phenyl) amino) -1,3,5-triazine-2,4-diyl diimino) bis- (2-ethylhexyl) ester of benzoic acid, 2-phenyl-5-methylbenzoxazole, 2, 2'-hydroxy-5-methylphenylbenzotriazole, 2- (2'-hydroxy-5'-t-octylphenyl) benzotriazole, 2- (2'-hydroxy-5'-methylphenyl) benzotriazole; dibenzazine; dianisoylmethane, 4-methoxy-4 "-butylbenzoylmethane, 5- (3,3-dimethyl-2-norbornylidene) -3-pentan-2-one, the family of diphenylacrylate derivatives such as 2-ethylhexyl-2- cyano-3,3-diphenyl-2-propenoate, ethyl-2-cyano-3,3-diphenyl-2-propenoate, the family of polysiloxanes such as benzylidene malonate siloxane.

Among the inorganic solar filters, also called "inorganic screens", which may be associated with the formulation for topical use object of the present invention as defined above, include titanium oxides, zinc oxides, cerium oxide, zirconium oxide, iron oxides yellow, red or black, chromium oxides. These inorganic screens may or may not be micronized, have undergone or not surface treatments and may be presented in the form of aqueous or oily pre-dispersions.

The present invention also relates to a method for preventing or slowing the appearance of dysaesthesic sensations on human sensitive skin comprising at least one step a) of applying to the surface of the skin to be treated with an effective amount of the formulation cosmetic as defined above.

By "effective amount" is meant in the definition of the method as defined above, an amount such that the slowing of dysaesthesic sensations on human skin shows an increase of at least 25% compared to the rate measured before the application of the formulation as defined above, on the surface of the epidermis of the skin to be treated, after a period of between seven days and twenty-one days after the application of said formulation on said surface of the epidermis treat.

Preferably, this method comprises a step b) of massage of the surface of the treated skin.

Finally, the present invention also objects:

- Seed oil of at least one umbelliferous plant as defined above, for use in a therapeutic treatment intended to prevent or slow the onset of dysaesthesic sensations on human sensitive skin.

formulation as defined above for use in a therapeutic treatment intended to prevent or slow the onset of dysaesthesic sensations on human sensitive skin.

Bibliography: (1): "Definition of Sensitive Skin: An Expert Paper Position from the Special Interest Group on

Sensitive Skin of the International Forum for the Study of Itch. "Misery, Stander, Szepietowski, Reich, Wallengren, Evers, Takamori, Brenaut, Gall-lanotto, Fluhr, Berardesca, Weisshaar Acta Derm Venereol 2017 Jan 4; l): 4-6)

(2): "Sensitive skin" Misery, Loser, Stander J Eur Acad Dermatol Venereol 2016 Feb; 30 Suppl 1: 2-8

(3): "Putative neuronal mechanisms of sensitive skin." Stander, Schneider, Weishaupt, Luger, Misery. Exp Dermatol. 2009 May; 18 (5): 417-23.

(4): "TRPV1 and TRPA1 in Neurogenic and Chronic Inflammation: Proinflammatory Response by Their Activation and Sensitization." Gouin, Herbella, Lebonvallet, Gall-lanotto, Sakka, Buhé, Plée-Gautier, Square, Lefeuvre, Misery, Le Garrec. Protein Cell. 2017 Sep; 8 (9): 644-661

(5): "Regulation of Pain and Itch by TRP Channels". Moore, Gupta, Jordt, Chen, Liedtke. Neurosci Bull. 2018 Feb; 34 (l): 120-142

(6): "Mediators of Chronic Pruritus in Atopy Dermatitis: Getting the Itch Out?" Mollanazar NK, Smith PK, Yosipovich G. Clin Rev Allergy Immunol. 2016 Dec; 51 (3): 263-292 (7): Yadav & Hot hay. "Cosmeceutical assets of ancient and contemporary ayurvedic astuteness". Int J Green Phar 2015, 9: S1-S6

(8): Coriander (Coriandrum sativum): "A promising functional food towards the well-being". Prachayasittikul, Prachayasittikul, Ruchirawat. Food Res Int 2018. 105: 305-323.

(9): "Anti-inflammatory potential of a lipolotion containing coriander oil in the ultraviolet erythema test." Reuters, Huyke, Casetti, Theek, Frank, Augustin, Schempp. J Dtsch Dermatol Ges. 2008 Oct; 6 (10): 847-51.

(10): "Study of the Anti-inflammatory Activity of Some Medicinal Edible Growing Plants in Egypt." Ammar, Al-Okbi, Mohamed. Med J Islamic World Acad Sci. 1997; 10 (4): 113-122 (11): Attia, Ibrahim, Maklad, Ahmed, Ramadan, and Der Pharma Chemica, Characterization of antiradical and anti-inflammatory activities of the cold pressed oils in carrageenan-induced rat model of acute inflammation. 2016, 8 (17): 148-158 »

(12): "Biochemical characterization, anti-inflammatory properties and ulcerogenic features of some cold-pressed oils in experimental animais". Ibrahim, Attia, Maklad, Ahmed, Ramadan. Pharm Biol. 2017 Dec; 55 (I): 740-748),

(13): "Evaluation of coriander spice as a functional food by using in vitro bioassays." Zhang, Dissanayake, Kevseroglu, Nair. Food Chemistry 2015, 167: 24-29

The following example illustrates the invention without limiting it.

The in vitro example described herein relates to the reduction of receptor activation, TR P A1, involved in the induction of itching / irritation / scratching / skin pain sensations following certain stimulations. Protection against activation of TRPA1 (Neuron Experts service)

® Principle of the method

Human sensory neurons were obtained from pluripotent stem cells and grown in culture plates. Human keratinocytes were amplified and seeded above the neurons. After 19 days of co-culture at 37 ° C., in a humid atmosphere at 5% CO 2, the products under test or the positive reference, HC030031 (C18H21N503), at 10 mM, as well as the fluorescent probe Fluo-4 AM, were added to the co-culture. The Fluo-4 AM probe tracks the rapid kinetics of variation in intracellular calcium concentration by measuring its fluorescence intensity in real time and the calcium flux is associated with the activation of TRPA1.

After 30 minutes of incubation, the culture medium was removed, the cultures were washed and then incubated again with the products under test. Immediately thereafter, they were placed under an inverted microscope and observed epi-fluorescence. The cells were observed for 3 minutes, a photograph was taken approximately every 333 ms. Five seconds after the start of the recording, the neurons were stimulated with AITC (allyl isothiocyanate) 10-3 M.

Statistical elements:

The experiments were performed in 6 replicates. Fluorescence was analyzed during

3 minutes.

Fluorescence values were expressed as averages +/- sem [standard error of the mean or standard error of the mean = standard deviation / root (number of values)].

For each condition, the percentages of stimulation and protection were calculated as follows:

% stimulation = 100 x [average (condition)] / [average (cells stimulated with AITC)]

% protection = 100 x [average (condition) - average (cells stimulated with TIAC)] / [average (unstressed cells) - average (cells stimulated with TIAC)].

The statistical analysis was performed by a one-way ANOVA test and a significance threshold of 5%, comparing the two-by-two conditions. A difference between the effectiveness of two products was considered:

- Significant if p <0.05;

- Say "at the limit of significance" if 0.05 £ p <0.1;

- and not significant if p> 0.1. ® Results

Table: Activation of TRPA1 following stimulation with AITC. * * * p <0.001 AITC induced a significant increase in the activation of TRPA1 (585% vs unstimulated cells) in the co-culture of keratinocytes-neurons.

HC30031, a TR P A1 antagonist, significantly reduced TRPA1 activation by 88%. And 0.001% coriander seed oil also significantly reduced TRPA1 activation by 61%.

® Conclusion

The coriander seed oil is able to reduce the activation of TRPA1 in a keratinocyte-human neuron co-culture model.

Claims

1. Seed oil of at least one umbelliferous plant administrable topically to prevent or slow the onset of dysaesthesic sensations on sensitive human skin.

2. Oil according to claim 1, characterized in that the umbelliferous plant is selected from coriander, chervil, celery, caraway, carrot, dill, parsley and fennel.

3. Oil according to claim 1, characterized in that the umbelliferous plant is coriander.

4. Oil according to one of claims 1 to 3, characterized in that it comprises for 100% of its mass a mass proportion of at least one triglyceride greater than or equal to 99%, with the triglyceride being a compound of formula ( I):

R ₁ -C (= O) -O-CH ₂ -CH [OC (= O) -R ₁ ] -CH ₂ -OC (= O) - R ₁ (I)

With R ₁ -C (= O) - acyl radical selected from the group consisting of palmitoyl (or hexadecanoyl), stearoyl (or octadecanoyl), petroselinoyl (or (Z) -octadec-6-enoyl), oleyl ( or cis-octadec-9-enoyl), and linoloyl (or cis, cis-9,12-octadecadienoyl), linolenoyl (or (9Z, 12Z, 15Z) -9,12,15-octadecatrienoyl)

5. Oil according to claim 4, characterized in that it comprises for 100% of the mass of triglycerides of formula (I) a mass quantity of between 40% and 85%, and more particularly between 55% and 80%, and even more particularly between 60% and 75%, of a triglyceride of formula (I) for which the radical R1C (= O) - is the petroselinoyl radical (or (Z) -octadec-6-enoyl).

6. Oil according to one of claims 4 or 5, characterized in that it comprises for 100% of the mass of triglycerides of formula (I):

a mass quantity of between 2% and 5% of a triglyceride of formula (I) for which the radical R1C (= O) - is the palmitoyl radical, and / or a mass quantity of between 0% and 1.5% of a triglyceride of formula (I) for which the radical R1C (= O) - is the stearoyl radical, and / or

a mass quantity of between 60% and 75% of a triglyceride of formula (I) for which the radical R1C (= O) - is the petroselinoyl (or (Z) -octadec-6-enoyl radical), and / or a mass quantity of between 8% and 15% of a triglyceride of formula (I) for which the radical R1C (= O) - is the oleyl radical, and / or

a mass quantity of between 12% and 19% of a triglyceride of formula (I) for which the radical R1C (= O) - is the linoleoyl radical, and / or

a mass quantity of 0% and 1% of a triglyceride of formula (I) for which the radical R1C (= O) - is the linolenoyl radical.

7. Cosmetic or dermatological formulation for topical use comprising for 100% of its mass:

from 50% to 99.5% by weight of at least one cosmetically acceptable ingredient.

8. Cosmetic or dermatological formulation according to claim 7, characterized in that it is in the form of an aqueous or hydro-alcoholic or hydro-glycolic solution, in the form of a suspension, an emulsion, a microemulsion or a nanoemulsion, whether water-in-oil, oil-in-water, water-in-oil-in-water or oil-in-water-in-oil, or form of a powder.

9. Cosmetic or dermatological formulation according to claim 8, characterized in that it is packaged in a vial, in a device of the "vial" pump type, an aerosol device in pressurized form, in a device provided with a perforated wall as a grid or in a device provided with a ball applicator.

10. Cosmetic or dermatological formulation according to one of claims 7 to 9, characterized in that the cosmetically acceptable ingredient is an excipient and / or an active ingredient.

11. Cosmetic or dermatological formulation according to claim 10, characterized in that the excipient and / or the active ingredient are selected from thickening and / or gelling surfactants, stabilizers, film-forming compounds, hydrotropic agents, plasticizing agents, emulsifiers and co-emulsifiers, opacifying agents, pearlescent agents, superfatting agents, sequestering agents, chelating agents, antioxidants, perfumes, preservatives, conditioners, whitening agents for hair discoloration and of the skin, the active principles intended to provide a treating action with respect to the skin or hair, sunscreens, mineral fillers or pigments, particles providing a visual effect or intended for the encapsulation of active ingredients, exfoliating particles and texture agents.

12. A method for preventing or slowing the onset of dysaesthesic sensations on human sensitive skin comprising at least one step a) of applying to the surface of the skin to be treated an effective amount of the cosmetic formulation as defined in US Pat. one of claims 7 to 11.

13. The method of claim 12, characterized in that it comprises a step b) massage the surface of the treated skin.

14. The seed oil of at least one umbelliferous plant as defined in one of claims 1 to 6, for use in a therapeutic treatment intended to prevent or slow the onset of dysaesthesic sensations on human sensitive skin.

15. A formulation as defined in any one of claims 7 to 11 for use in a therapeutic treatment for preventing or slowing the onset of dysaesthesic sensations on human sensitive skin.